Anti-CD19 Reference Antibody (obexelimab) is utilized as a research tool in biopharmaceutical development, particularly for studying autoimmune diseases such as systemic lupus erythematosus (SLE) and other B-cell-mediated disorders, as well as B-cell malignancies like leukemia and lymphoma. It selectively targets CD19, a protein expressed on B cells, facilitating the investigation of B-cell depletion mechanisms that preserve plasma cells and early B-cell precursors, potentially reducing autoimmune activity with fewer side effects compared to broad immunosuppressants.

In drug development processes, this antibody serves as a reference standard to compare the efficacy of commercial or experimental antibodies, ensuring accuracy in analyses such as binding affinity measurements or immune response evaluations.

Additionally, obexelimab has potential as a control in laboratory diagnostic systems, such as detecting B cells in blood or tissue samples, which is crucial for diagnosing and monitoring immune-related diseases. The molecule itself is currently under clinical investigation to assess its long-term efficacy and safety in modulating B-cell function for therapeutic applications.